Reported Late Wednesday, AbbVie's Pharmacyclics Alleges BeiGene's Brukinsa Blood Cancer Drug Infringes Imbruvica Patent
Portfolio Pulse from Benzinga Newsdesk
AbbVie's Pharmacyclics has alleged that BeiGene's blood cancer drug Brukinsa infringes on its Imbruvica patent. The claim was reported late Wednesday.
June 15, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Pharmacyclics alleges BeiGene's Brukinsa infringes on its Imbruvica patent, potentially affecting AbbVie's market share.
If the infringement claim is proven, AbbVie may face increased competition from BeiGene's Brukinsa, which could negatively impact its market share and revenue from Imbruvica. This may lead to a short-term negative impact on AbbVie's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
BeiGene's Brukinsa is accused of infringing on AbbVie's Imbruvica patent, which may lead to legal disputes and potential financial consequences.
If the infringement claim is proven, BeiGene may face legal disputes and potential financial consequences, such as fines or loss of revenue from Brukinsa. This may lead to a short-term negative impact on BeiGene's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100